IP Library Granted Patent US 9,561,176
Granted Patent B2
US 9,561,176 · App. 14/878,232 · Granted Feb 7, 2017

Methods of intravenous administration of glyburide

Inventor: Sven Martin Jacobson (New York, NY)
Assignee: Remedy Pharmaceuticals, Inc.
A61K9/0019A61K31/17A61K31/18A61K31/64
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,561,176
App. No.
14/878,232
Granted
Feb 7, 2017
Kind
B2
Abstract

The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 μg/hr and about 300 μg/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.

Claims (35)

1. A method of treating a patient in need of treatment, comprising:

identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia;

administering a bolus of glyburide to the patient; and

administering a continuous infusion of glyburide to the patient ranging from 15 μg/hr to 300 μg/hr, wherein the continuous infusion glyburide is administered for about 20 hours or more.

2. The method of claim 1 , wherein the step of administering the continuous infusion of glyburide is after administering the bolus of glyburide.

3. The method of claim 1 , wherein the continuous infusion of glyburide is administered for about 30 hours or more.

4. The method of claim 1 , wherein the continuous infusion of glyburide is administered for about 40 hours or more.

5. The method of claim 1 , wherein the continuous infusion of glyburide is administered for about 50 hours or more.

6. The method of claim 1 , wherein the continuous infusion of glyburide is administered for about 60 hours or more.

7. The method of claim 1 , wherein the continuous infusion of glyburide is administered for about 70 hours or more.

8. The method of claim 1 , wherein the continuous infusion of glyburide is administered for about 72 hours or more.

9. The method of claim 1 , wherein the continuous infusion of glyburide is for about 4 days or more.

10. The method of claim 1 , wherein the continuous infusion of glyburide is for about 5 days or more.

11. The method of claim 1 , wherein the step of administering the bolus occurs in about 3 minutes or less.

12. The method of claim 1 , wherein the bolus of glyburide ranges from 125 μg to 150 μg.

13. The method of claim 1 , wherein the continuous infusion of glyburide is divided over two or more continuous infusion rates, including a first continuous infusion rate followed by a second continuous infusion rate.

14. The method of claim 13 , wherein the first continuous infusion rate is greater than the second continuous infusion rate.

15. The method of claim 13 , wherein the first continuous infusion rate and the second continuous infusion rate are each about 15 μg/hr and about 300 μg/hr, respectively.

16. The method of claim 13 , wherein the first continuous infusion rate ranges from 150 μg/hr to 175 μg/hr of glyburide.

17. The method of claim 13 , wherein the second continuous infusion rate ranges from 100 μg/hr to 125 μg/hr glyburide.

18. The method of claim 13 , wherein the first continuous infusion rate is administered for a period of time ranging from 1 hour to 10 hours.

19. The method of claim 13 , wherein the second continuous infusion rate is administered for about 66 hours, and where the sum of the first continuous infusion rate and of the second continuous infusion rate are administered for a total period of time of about 72 hours.

20. The method of claim 13 , wherein the step of administering the bolus of glyburide to the patient is at about 130 μg of glyburide, followed by the first continuous infusion rate of about 163 μg/hr glyburide for 6 hours, followed by the second continuous infusion rate of about 112 μg/hr glyburide for 66 hours.

21. The method of claim 1 , wherein the treatment is for stroke.

22. The method of claim 21 , wherein the stroke is ischemic stroke.

23. The method of claim 21 , wherein the stroke is hemorrhagic stroke.

24. The method of claim 1 , wherein the treatment is for traumatic brain injury.

25. The method of claim 1 , wherein the treatment is for spinal cord injury.

26. The method of claim 1 , wherein the treatment is for myocardial infarction.

27. The method of claim 1 , wherein the treatment is for ischemic shock.

28. The method of claim 1 , wherein the treatment is for hemorrhagic shock.

29. The method of claim 1 , wherein the treatment is for organ ischemia.

30. The method of claim 1 , wherein the treatment is for ventricular arrhythmias.

31. The method of claim 1 , wherein the treatment is for ischemic injury.

32. The method of claim 1 , wherein the treatment is for hypoxia/ischemia.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2023
From: BIOGEN CHESAPEAKE LLC
To: REMEDY PHARMACEUTICALS, INC.
Reel/Frame 064678/0502 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2017
From: REMEDY PHARMACEUTCALS, INC.
To: BIOGEN CHESAPEAKE LLC
Reel/Frame 042785/0401 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2015
From: JACOBSON, SVEN
To: REMEDY PHARMACEUTICALS, INC.
Reel/Frame 036756/0954 →
Continuity (4)
Continuation 14525992 · Oct 28, 2014
Continuation 13811037
Provisional Application 61365689 · Jul 19, 2010
Related Publication 20160030370A1 · Feb 4, 2016